Alvotech Doubles U.S. Biosimilar Production Capacity with FDA Approval

  • FDA approved additional U.S. manufacturing capacity for Alvotech's biosimilar SIMLANDI® (adalimumab-ryvk), doubling production capacity at its Reykjavik facility.
  • Approval enables AVT02 drug substance to be manufactured in either of two production suites (DSM1 or DSM2) at the Reykjavik site.
  • Resolution of FDA inspection-related matters at the Reykjavik site confirmed, paving the way for other pending regulatory applications.
  • Alvotech's strategic partner Teva Pharmaceuticals handles exclusive commercialization of SIMLANDI® in the U.S.
  • AVT02 is approved in over 50 countries and marketed under various names globally.

The FDA's approval of additional manufacturing capacity for SIMLANDI® strengthens Alvotech's operational flexibility and regulatory standing in the U.S. biosimilar market. This move comes as the biosimilar industry continues to expand, driven by patent expirations of blockbuster biologics and increasing demand for cost-effective treatments. Alvotech's ability to resolve regulatory issues and scale production could position it as a key player in the global biosimilar space, particularly as it navigates competition from established pharmaceutical giants and emerging biotech firms.

Regulatory Momentum
Whether the FDA's resolution of inspection-related matters will accelerate approvals for Alvotech's other pending biosimilar applications.
Market Competition
How Alvotech's expanded production capacity will impact its competitive positioning against Humira and other biosimilar players in the U.S. market.
Operational Flexibility
The pace at which Alvotech can leverage the additional manufacturing capacity to support commercial supply and potential new product launches.